← Back to Search

Cannabinoid

Full Spectrum Cannabidiol for Mild Cognitive Impairment

Phase 2
Recruiting
Research Sponsored by University of Colorado, Denver
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Able to attend in-person visits at the study site
Functional Activities Questionnaire (FAQ) score of 8 or less and self-reported ability to function independently
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 0 to week 24
Awards & highlights

Study Summary

This trial aims to test how CBD affects the progression of Alzheimer's disease by looking at various biomarkers and measures, using a randomized and double-blind approach.

Who is the study for?
This trial is for individuals aged 55-85 who have been diagnosed with Mild Cognitive Impairment (MCI) at the University of Colorado School of Medicine. They must show specific signs of cognitive decline but not full-blown dementia, as indicated by a score of .5 on the Clinical Dementia Rating scale.Check my eligibility
What is being tested?
The study is testing whether cannabidiol (CBD), a compound found in cannabis plants, can slow down or affect Alzheimer's disease progression compared to a placebo. Participants won't know if they're getting CBD or the placebo in this double-blind study.See study design
What are the potential side effects?
While not specified here, CBD may cause side effects such as tiredness, diarrhea, changes in appetite/weight and could interact with other medications. The exact side effects will be monitored throughout the trial.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I can go to the study site for visits.
Select...
I can do daily activities on my own and my FAQ score is 8 or less.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 0 to week 24
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 0 to week 24 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Biomarkers of Alzheimer's Disease Progression
Neurocognitive Function
Secondary outcome measures
Change in anxiety
Change in pain
Change in plasma lipid biomarkers of inflammation and oxidative stress
+1 more

Trial Design

3Treatment groups
Active Control
Placebo Group
Group I: Full Spectrum CannabidiolActive Control1 Intervention
200mg/day of full-spectrum cannabidiol, containing less than 0.3% THC.
Group II: Broad Spectrum CannabidiolActive Control1 Intervention
200mg/day of broad-spectrum cannabidiol, containing 0.0% THC.
Group III: Hemp Seed OilPlacebo Group1 Intervention
200mg/day of hemp seed oil with no cannabinoids present.

Find a Location

Who is running the clinical trial?

University of Colorado, DenverLead Sponsor
1,749 Previous Clinical Trials
2,163,824 Total Patients Enrolled
~157 spots leftby Apr 2028
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top